Dual Obstructive Sleep Apnea (OSA) Therapy (MAS With PAP)
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 30
- Locations
- 2
- Primary Endpoint
- Change in CPAP Pressure
Study Overview
Brief Summary
Continuous positive airway pressure (CPAP) is considered the gold standard therapy for obstructive sleep apnea (OSA). However, CPAP users sometimes experience pressure-related discomfort. It is thought that lower CPAP pressure may increase comfort and lead to greater treatment adherence.
Mandibular advancement splint (MAS) therapy has been shown to be the preferred OSA treatment option among patients. However, MAS therapy is only partially effective in some OSA patients, especially in severe cases.
It is thought that a combination of MAS and PAP therapy may benefit patients in which MAS alone is only partially effective. Using MAS and PAP at the same time is called "Dual Therapy". Dual Therapy may allow a lower CPAP pressure to be applied, which may increase patient comfort and therefore increase treatment adherence and overall effectiveness.
This study will evaluate the effectiveness of 1 month of Dual Therapy in 30 OSA patients.
Detailed Description
This is a prospective clinical trial assessing the effect of 1-month of dual therapy on patients with varying baseline OSA severity (mild to severe) who have been previously fully titrated to both PAP and MAS.
This study will be conducted at 2 research centers; the Faculty of Dentistry, University of British Columbia (UBC), Vancouver and at the Faculty of Dentistry, Université de Montréal (UdM), Montréal.
The research team will access participants' records to confirm eligibility for dual therapy. The clinical research coordinator will contact eligible patients via phone to ask if they are interested in taking part in the study. Eligible patients will also be asked if they are interested in taking part in the study during routine clinic visits. Where possible, patients will not be approached by their primary caregiver regarding participation in this study, to ensure patients do not feel pressurized into participating. Choosing not to take part in the study will not affect the participants' quality of care. If a patient is interested in taking part in the study they will be invited to review and sign the informed consent form.
Consenting participants will be asked to use both MAS and PAP (dual therapy) together for a period of 1 month. During the first week of the dual therapy, PAP pressure will be adjusted automatically for a 1-week period, after which the pressure will be set remotely by the Respiratory Therapist at the 90th percentile.
With permission, the research team will access the Sleep Apnea Dental Clinic records to collect data relating to previous treatment with MAS and PAP monotherapies. Data collected includes: PAP pressure, treatment adherence, subjective treatment assessment, Epworth Sleepiness Scale (ESS) and Functional Outcomes of Sleep Questionnaires (FOSQ), weight, blood pressure and oximetry data.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 19-80 years old who are able to freely provide informed consent;
- •Prior participation in the CHOICE study;
- •Have been optimally titrated to PAP and MAS therapy;
- •Have both PAP and MAS appliances at home and ready for use;
- •Body mass index (BMI) of 35 or less;
- •≥ 8 teeth per arch to support treatment with MAS;
- •Have an objective of diagnosis of OSA based on the following criteria:
- •- an Apnea-Hypopnea Index (AHI) within the range 10 ≤ AHI ≤ 70 documented with polysomnography in the last 2 years; ***OR***
- •- a Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 70 documented with level III portable sleep test; ***OR***
- •- an Oxygen Desaturation Index (ODI) ≥ 10;
- •Sleep investigations confirming the object diagnosis of OSA have been performed within the past 4 years
Exclusion Criteria
- •Use of a full face mask as the PAP interface;
- •Extensive periodontal disease with significant tooth mobility;
- •Inability to protrude jaw;
- •Insufficient vertical opening to accommodate treatment with MAS;
- •Uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an ejection cut-off of 40% or clinical sign in the opinion of a primary care physician or cardiologist) that makes it unsafe in the opinion of the investigators for the subject to participate in the trial;
- •Coronary artery disease unless stable for at least 6 months and considered by the investigators to have a stable disease;
- •Any history of angina, myocardial infarction or stroke;
- •Any history of major depressive disorder along with current moderate-severe disease;
- •Active cancer management (unless in remission for more than 1 year);
- •Known renal failure (with need for dialysis);
- •History of a near miss or prior automobile accident due to sleepiness within the past 12 months;
- •At nighttime, 30% of the night is at ≤ 90% oxygen saturation levels.
Arms & Interventions
Treatment Group
This group will undergo 1 month Dual Therapy.
Intervention: Dual Therapy (Combination Product)
Outcomes
Primary Outcomes
Change in CPAP Pressure
Time Frame: Baseline (from previous treatment with CPAP) and 1 month after commencing Dual Therapy treatment.
Optimal CPAP Pressure determined by the Respiratory Therapist (cmH2O)
Treatment Adherence (hrs/night)
Time Frame: The duration of Dual Therapy treatment (1 month).
Adherence measured in hours per night.
Comfort
Time Frame: Baseline (from previous treatment) and 1 month after commencing Dual Therapy treatment.
A subjective assessment of the Dual Therapy treatment, reported via a questionnaire.
Treatment Adherence (% nights)
Time Frame: The duration of Dual Therapy treatment (1 month).
Adherence measured in percentage of nights of use.
Secondary Outcomes
- Efficacy - Time below 90% Saturation(Baseline (from previous treatment) and 1 month after commencing Dual Therapy treatment.)
- Efficacy - Oxygen Desaturation Index(Baseline (from previous treatment) and 1 month after commencing Dual Therapy treatment.)
- Daytime Sleepiness(Baseline (from previous treatment) and 1 month after commencing Dual Therapy treatment.)
- Quality of Life using Functional Outcomes of Sleep Questionnaire (FOSQ-10)(Baseline (from previous treatment) and 1 month after commencing Dual Therapy treatment.)
- Efficacy - Minimum Saturation(Baseline (from previous treatment) and 1 month after commencing Dual Therapy treatment.)
Investigators
Fernanda Almeida
Associate Professor
University of British Columbia